Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Type of study
Language
Document Type
Year range
1.
Indian Pediatrics ; 58(6):525-531, 2021.
Article in English | Scopus | ID: covidwho-1303381

ABSTRACT

Background: Limited evidence exists on perinatal transmission and outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in neonates. Objective: To describe clinical outcomes and risk factors for transmission in neonates born to mothers with perinatal SARS-CoV-2 infection. Design: Prospective cohort of suspected and confirmed SARS-CoV-2 infected neonates entered in National Neonatology Forum (NNF) of India registry. Subjects: Neonates born to women with SARS-CoV-2 infection within two weeks before or two days after birth and neonates with SARS-CoV-2 infection. Outcomes: Incidence and risk factors of perinatal transmission. Results: Among 1713 neonates, SARS-CoV-2 infection status was available for 1330 intramural and 104 extramural neonates. SARS-CoV-2 positivity was reported in 144 intramural and 39 extramural neonates. Perinatal transmission occurred in 106 (8%) and horizontal transmission in 21 (1.5%) intramural neonates. Neonates roomed-in with mother had higher transmission risk (RR1.16, 95% CI 1.1 to 2.4;P=0.01). No association was noted with the mode of delivery or type of feeding. The majority of neonates positive for SARS-CoV2 were asymptomatic. Intramural SARS-CoV-2 positive neonates were more likely to be symptomatic (RR 5, 95%CI 3.3 to 7.7;P<0.0001) and need resuscitation (RR 2, 95%CI 1.0 to 3.9;P=0.05) compared to SARS-CoV-2 negative neonates. Amongst symptomatic neonates, most morbidities were related to prematurity and perinatal events. Conclusion: Data from a large cohort suggests perinatal transmission of SARS-CoV-2 infection and increased morbidity in infected infants. © 2021, Indian Academy of Pediatrics.

2.
International Journal of Pharmaceutical Sciences Review and Research ; 65(2):160-164, 2020.
Article in English | EMBASE | ID: covidwho-1077128

ABSTRACT

The world is ravaged by SARS-CoV-2 infection with more than 45 million cases and 1 million deaths worldwide. And the rate of infection is nowhere appears to slow down. This unprecedented magnitude of pandemic in recent times pushed the world into a state of despair. Currently no treatment is approved and most of the choices are under clinical trials. All the treatment options have to pass through the rigorous studies to get approved. This must take a very long time. In this article, we are evaluating some of the therapeutic options available currently to tackle the COVID-19 at least until a definite treatment or vaccine is available. And we tried to present the differences between flu and COVID-19 and also the past Coronavirus epidemics versus the COVID-19.

SELECTION OF CITATIONS
SEARCH DETAIL